Valuation : ICAD

Market Cap 106M 90.99M 85.31M 77.88M 147M 10.09B 147M 1.01B 395M 5.09B 396M 388M 16.89B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 76.48M 71.7M 65.45M 123M 8.48B 124M 851M 332M 4.28B 333M 326M 14.2B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
12.73
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 2023-03-09
Director of Finance/CFO 54 2025-07-16
Corporate Secretary - 2025-07-16
Date Insider Type Main position Quantity % Market Cap.
7/17/25 Issuer sale

Director

1,553,657 5.8540%
7/17/25 Issuer sale

Chief Financial Officer

158,488 0.5972%
7/17/25 Issuer sale

Chief Technology Officer

351,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%-.--%+73.54% 106M
-1.35%-1.13%+26.27%+12.02% 230B
+0.18%-1.27%+4.98%-18.16% 152B
+1.51%-1.64%-21.28%+20.04% 132B
+0.36%-7.01%-55.60%-14.34% 67.88B
+0.29%+0.47%+10.90%+15.91% 52B
+0.66%-1.69%-16.47%-14.35% 51.05B
-2.44%-3.25%+22.43%+26.08% 43.38B
-1.56%+0.97%+37.41%+44.08% 40.74B
+1.94%+3.81%-12.45%+46.61% 34.67B
Average +0.33%-0.75%-0.38%+19.14% 80.34B
Weighted average by Cap. -0.14%-1.29%+2.51%+7.86%

Financials

2023 2024
Net sales 17.32M 14.92M 13.99M 12.77M 24.06M 1.66B 24.14M 166M 64.77M 836M 65.02M 63.61M 2.77B 19.61M 16.9M 15.84M 14.46M 27.24M 1.87B 27.33M 188M 73.33M 946M 73.62M 72.02M 3.14B
Net income -4.85M -4.18M -3.92M -3.57M -6.73M -463M -6.76M -46.46M -18.13M -234M -18.2M -17.8M -775M -5.62M -4.84M -4.54M -4.14M -7.8M -537M -7.83M -53.83M -21M -271M -21.09M -20.63M -898M
Net Debt -21.21M -18.28M -17.14M -15.64M -29.47M -2.03B -29.56M -203M -79.32M -1.02B -79.63M -77.9M -3.39B -16.84M -14.51M -13.61M -12.42M -23.4M -1.61B -23.48M -161M -62.99M -813M -63.24M -61.86M -2.69B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock